Frequency of Increased Maintenance Doses of Adalimumab, Etanercept, And Ustekinumab

Abstract

exceeding the FDA label recommendations of ADA 40 mg biweekly, ETN 50 mg weekly, and UST 45 mg every 12 weeks. RESULTS: In total, 15,400 PsA patients and 40,545 PSO patients met the inclusion criteria. The number (proportion) of patients receiving increased maintenance doses for PsA was1,603 of 8,908 (18%) for ADA and 1,300 of 7,647 (17%) for ETN. The number (proportion) of patients receiving increased maintenance doses for PSO was 3,187 of 21,234 (15%) for ADA; 5,201 of 16,318 (32%) for ETN; and 3,136 of 6,915 (45%) for UST. CONCLUSIONS: A large subgroup of patients treated with commonly used biologic agents is maintained on increased maintenance doses.